While US President Trump is pushing to link US drug prices to overseas low-cost markets, a number of major US and European pharmaceutical companies recently reached an agreement with the White House to voluntarily lower the prices of drugs sold in the US in exchange for tariff exemptions and policy support. The Trump administration is restarting the “most-favoured-nation drug price” policy in an attempt to reduce the high cost of prescription drugs in the US through administrative measures.

While US President Trump is pushing to link US drug prices to overseas low-cost markets, a number of major US and European pharmaceutical companies recently reached an agreement with the White House to voluntarily lower the prices of drugs sold in the US in exchange for tariff exemptions and policy support. The Trump administration is restarting the “most-favoured-nation drug price” policy in an attempt to reduce the high cost of prescription drugs in the US through administrative measures.